Zevra Therapeutics, Inc. ZVRA Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Zevra Therapeutics, Inc. (ZVRA) reported accretion (amortization) of discounts and premiums, investments of $624K in Q1 2026.
- How has Zevra Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Zevra Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments increased by 104.6% year-over-year, from $305K to $624K.
- What does accretion (amortization) of discounts and premiums, investments mean?
- Measures the non-cash adjustment to the carrying value of investment securities to reflect the amortization of premiums or accretion of discounts over the life of the instrument. This adjustment aligns the reported interest income with the effective interest method, impacting the reconciliation of net income to cash flow.